keyword
MENU ▼
Read by QxMD icon Read
search

ius levonorgestrel

keyword
https://www.readbyqxmd.com/read/28330857/estimated-disability-adjusted-life-years-averted-by-free-of-charge-provision-of-the-levonorgestrel-releasing-intrauterine-system-over-a-9-year-period-in-brazil
#1
Jessica M Ferreira, Ilza Monteiro, Arlete Fernandes, Maria V Bahamondes, Ana Pitoli, Luis Bahamondes
BACKGROUND: The objective was to analyse the contribution of the provision at no cost to users of the 20 µg/day levonorgestrel-releasing intrauterine system (LNG-IUS) towards disability-adjusted life years (DALY) averted over a 9-year period. METHODS: We analysed data from 15 030 new users of the LNG-IUS who had the device inserted at 26 Brazilian teaching hospitals between January 2007 and December 2015. The devices came from the International Contraceptive Access Foundation (ICA), a not-for-profit foundation that donates the devices to developing countries for use by low-income women who desire long-term contraception and who freely choose to use this device...
March 22, 2017: Journal of Family Planning and Reproductive Health Care
https://www.readbyqxmd.com/read/28299789/menstrual-management-in-developmentally-delayed-adolescent-females
#2
Irene Chuah, Alexandra McRae, Kim Matthews, Ann M Maguire, Katharine Steinbeck
BACKGROUND: Requests for assistance in menstrual management and menstrual suppression are a common, emotive and sometimes controversial aspect of adolescent disability care. AIMS: To review the uptake and outcomes of menstrual suppression among adolescent patients with developmental delay. METHODS: A retrospective review of the medical records of adolescent females with intellectual disability referred for menstrual management to the Paediatric and Adolescent Gynaecology Clinic, Children's Hospital at Westmead, Sydney, for the three-year period between January 1, 2010 and January 1, 2013...
March 15, 2017: Australian & New Zealand Journal of Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28283026/preventing-recurrence-of-endometriosis-by-means-of-long-acting-progestogen-therapy-pre-empt-report-of-an-internal-pilot-multi-arm-randomised-controlled-trial-incorporating-flexible-entry-design-and-adaption-of-design-based-on-feasibility-of-recruitment
#3
Lee J Middleton, Jane P Daniels, Annalise Weckesser, Siladitya Bhattacharya
BACKGROUND: Endometriosis is associated with the growth of endometrium in ectopic sites mainly within the pelvis. This results in inflammation and scarring, causing pain and impaired quality of life. Endometriotic lesions can be excised or ablated surgically, but the risk of recurrence is high. A Heath Technology Assessment commissioning call in 2011 sought applications for trials aimed at evaluating long-term effectiveness of postoperative, long-acting, reversible contraceptives (LARCs) in preventing recurrence of endometriosis...
March 11, 2017: Trials
https://www.readbyqxmd.com/read/28262240/heavy-menstrual-bleeding-an-update-on-management
#4
Joanna Davies, Rezan A Kadir
Heavy menstrual bleeding (HMB) is defined as excessive menstrual blood loss (MBL) >80 mL per cycle, that interferes with a woman's physical, emotional, social wellbeing and quality of life. Aetiology is due to underlying uterine pathologies, coagulopathy, ovulation dysfunction, or iatrogenic. Up to 20% of women with HMB will have an underlying inherited bleeding disorder (IBD). Assessment of HMB should entail a menstrual and gynaecological history and a bleeding score to distinguish those women who require additional haematological investigations...
March 2017: Thrombosis Research
https://www.readbyqxmd.com/read/28256913/family-planning-and-zika-virus-need-for-renewed-and-cohesive-efforts-to-ensure-availability-of-intrauterine-contraception-in-latin-america-and-the-caribbean
#5
Moazzam Ali, Kelsey Miller, Rodolfo Federico Gómez Ponce de Leon
OBJECTIVES: The advantages of intrauterine contraception (IUC) are well established (highly effective, low discontinuation rate, easy to use, low cost, and suitable for immediate postpartum use), but low levels of use in many countries and declining use in others are causes for concern. Due to the ongoing Zika virus outbreak, public health officials are calling for the continued practice of safe sex and the delay of pregnancy. Our study was conducted to assess the current situation of IUC availability and provision in Latin America and to determine the role of national policies in meeting the contraceptive needs of the populations in these countries...
April 2017: European Journal of Contraception & Reproductive Health Care
https://www.readbyqxmd.com/read/28238590/the-current-status-of-hormonal-therapies-for-heavy-menstrual-bleeding
#6
REVIEW
Oskari Heikinheimo, Ian Fraser
Hormonal treatment of abnormal uterine bleeding (AUB), especially bleeding related to endometrial causes (AUB-E), ovulatory dysfunction (AUB-O) and coagulopathy (AUB-C), and to some extent, uterine leiomyomas and adenomyosis, has become the first-line evidence-based management strategy during recent years. Hormonal treatment of heavy menstrual bleeding (HMB) is also endorsed as the first line of treatment in several international guidelines. In the present article, we review the efficacy of the commonly used and widely available hormonal treatments of AUB-O, AUB-E and AUB-C...
January 21, 2017: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28209488/postoperative-maintenance-levonorgestrel-releasing-intrauterine-system-and-endometrioma-recurrence-a%C3%A2-randomized-controlled-study
#7
Yi-Jen Chen, Teh-Fu Hsu, Ben-Shian Huang, Hsiao-Wen Tsai, Yen-Hou Chang, Peng-Hui Wang
BACKGROUND: According to 3 randomized trials, the levonorgestrel-releasing intrauterine system significantly reduced recurrent endometriosis-related pelvic pain at postoperative year 1. Only a few studies have evaluated the long-term effectiveness of the device for preventing endometrioma recurrence, and the effects of a levonorgestrel-releasing intrauterine system as a maintenance therapy remain unclear. OBJECTIVE: The objective of the study was to evaluate whether a maintenance levonorgestrel-releasing intrauterine system is effective for preventing postoperative endometrioma recurrence...
February 15, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28176932/intrauterine-levonorgestrel-delivery-with-frameless-fibrous-delivery-system-review-of-clinical-experience
#8
REVIEW
Dirk Wildemeersch, Amaury Andrade, Norman D Goldstuck, Thomas Hasskamp, Geert Jackers
The concept of using a frameless intrauterine device (IUD) instead of the conventional plastic framed IUD is not new. Frameless copper IUDs have been available since the late 1990s. They rely on an anchoring system to retain in the uterine cavity. The clinical experience with these IUDs suggests that frameless IUDs fit better as they are thin and, therefore, do not disturb or irritate the uterus. High tolerance and continuation rates have been achieved as complaints of pain are virtually nonexistent and the impact on menstrual blood loss is minimal...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/28142308/a-case-of-endometrial-carcinoma-in-a-long-term-levonorgestrel-intrauterine-system-lng-52%C3%A2-mg-ius-user
#9
Melisa Thomas, Paula Briggs
This report describes a 50-year-old woman who presented to a community gynaecology clinic complaining of persistent heavy vaginal bleeding with an LNG 52 mg-IUS in situ. She was subsequently found to have stage 1 grade 1a endometrioid carcinoma. From the literature, we have identified five similar cases. This case highlights the possibility of endometrial carcinoma despite treatment with an LNG 52 mg-IUS and reinforces the importance of investigating women who present with unusual persistent or heavy vaginal bleeding...
January 1, 2017: Post Reproductive Health
https://www.readbyqxmd.com/read/28041992/changes-in-body-composition-in-women-using-long-acting-reversible-contraception
#10
Priscilla de Nazaré Silva Dos Santos, Tessa Madden, Karen Omvig, Jeffrey F Peipert
OBJECTIVE: Users of hormonal long-acting reversible contraception (LARC) report weight gain as a side effect, but few studies have assessed body composition change among LARC users. We evaluated weight and body composition of healthy women using the levonorgestrel intrauterine system (LNG-IUS), copper intrauterine device (copper IUD) or etonogestrel implant (ENG implant). We hypothesized that weight gain and body composition over 12 months would not differ between copper IUD, LNG-IUS and ENG implant users...
December 30, 2016: Contraception
https://www.readbyqxmd.com/read/28012273/timing-of-insertion-of-levonorgestrel-releasing-intrauterine-system-a-randomised-controlled-trial
#11
Pahh van der Heijden, Pmaj Geomini, M C Herman, S Veersema, M Y Bongers
OBJECTIVE: The objective was to assess whether patient-perceived pain during the insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) depends on the timing during the menstrual cycle. DESIGN: A stratified two-armed non-inferiority randomised controlled trial. SETTING: Large teaching hospital in Veldhoven, the Netherlands. SAMPLE: From October 2013 to May 2014, 60 nulliparous and 60 multiparous women were randomised...
January 2017: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/27990196/levonorgestrel-releasing-intrauterine-system-52-mg-for-idiopathic-heavy-menstrual-bleeding-a-health-technology-assessment
#12
REVIEW
(no author information available yet)
BACKGROUND: Heavy menstrual bleeding affects as many as one in three women and has negative physical, economic, and psychosocial impacts including activity limitations and reduced quality of life. The goal of treatment is to make menstruation manageable, and options include medical therapy or surgery such as endometrial ablation or hysterectomy. This review examined the evidence of effectiveness and cost-effectiveness of the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS) as a treatment alternative for idiopathic heavy menstrual bleeding...
2016: Ontario Health Technology Assessment Series
https://www.readbyqxmd.com/read/27984850/development-of-endometrioid-adenocarcinoma-despite-levonorgestrel-releasing-intrauterine-system-a-case-report-with-discussion-and-review-of-the-rcog-bsge-guideline-on-the-management-of-endometrial-hyperplasia
#13
A C L van der Meer, L S Hanna
Obesity is a significant risk factor for the development of endometrial hyperplasia and cancer. More conservative prevention and management strategies are attractive due to the increased surgical risk and complication rates associated with obesity. The Levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena) has been shown to reduce the risk of developing endometrial cancer. The recent joint Green Top Guideline on the Management of Endometrial Hyperplasia published by the Royal College of Obstetricians and Gynaecologists (RCOG) with the British Society for Gynaecological Endoscopy (BSGE) recommends the LNG-IUS for the medical management of endometrial hyperplasia without atypia...
February 2017: Clinical Obesity
https://www.readbyqxmd.com/read/27971668/levonorgestrel-intrauterine-system-and-norethisterone-for-the-treatment-of-chronic-abnormal-uterine-bleeding-a-randomized-clinical-comparison-in-the-patients-of-bahawalpur-pakistan
#14
M N Ashraf, G Murtaza
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970722/cost-effectiveness-analysis-of-52-mg-levonorgestrel-releasing-intrauterine-system-lng-ius-versus-short-acting-hormonal-contraceptives-in-avoiding-unintended-pregnancy-up-in-15-to-19-year-old-adolescents-under-the-brazilian-public-healthcare-system-sus
#15
A Honda, N B Ramos, M Sakagute, C Nakada, F Tobaruella
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970711/budget-impact-analysis-bia-of-the-introduction-of-52mg-levonorgestrel-releasing-intrauterine-system-lng-ius-as-a-contraceptive-method-option-in-the-brazilian-public-healthcare-system-sus-to-avoid-unintended-pregnancy-up-in-15-to-19-year-old-adolescents
#16
N B Ramos, A Honda, M Sakagute, C Nakada, F Tobaruella
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27957732/chronic-vulvovaginal-candidiasis-in-patients-using-a-levonorgestrel-containing-intrauterine-device
#17
Yvonne Nguyen, Gayle Fischer
Chronic vulvovaginal candidiasis is usually responsive to therapy with oral antifungals. We present a case series of 13 patients with this condition who were also using a levonorgestrel intrauterine system (LNG-IUS). All cases responded to ongoing oral fluconazole therapy while the LNG-IUS was in situ. The LNG-IUS was removed in six patients and of these, two experienced clinical improvement with lower fluconazole dosage requirements and three experienced complete resolution of symptoms. One remains on fluconazole 100 mg daily...
December 13, 2016: Australasian Journal of Dermatology
https://www.readbyqxmd.com/read/27940059/use-of-the-levonorgestrel-52-mg-intrauterine-system-in-adolescent-and-young-adult-solid-organ-transplant-recipients-a-case-series
#18
P S Huguelet, C Sheehan, R F Spitzer, S Scott
This case series reports on the safety and efficacy of the levonorgestrel 52-mg intrauterine system in adolescent and young adult solid organ transplant recipients. All patients used the device for contraception, with no documented cases of disseminated pelvic infection or unplanned pregnancy.
December 7, 2016: Contraception
https://www.readbyqxmd.com/read/27932442/contraceptive-sales-in-the-setting-of-the-zika-virus-epidemic
#19
Luis Bahamondes, Moazzam Ali, Ilza Monteiro, Arlete Fernandes
STUDY QUESTION: Has there been any influence of the Zika virus (ZIKV) outbreak on the sales of contraceptive methods in Brazil? SUMMARY ANSWER: Contraceptive sales in the 24 months of evaluation showed little variation and no significant change has been observed since the ZIKV outbreak. WHAT IS KNOWN ALREADY: Transmission of ZIKV is primarily by Aedes aegypti mosquitoes; however, sexual transmission has also been described. The association of several birth defects and the ZIKV infection during pregnancy has been established, and it was estimated in Bahia, Brazil that the infection rate could range from 10% to 80%...
January 2017: Human Reproduction
https://www.readbyqxmd.com/read/27930941/evaluation-of-a-new-low-dose-levonorgestrel-intrauterine-contraceptive-system-over-5-years-of-use
#20
Kristina Gemzell-Danielsson, Dan Apter, Sylvia Dermout, Thomas Faustmann, Kimberly Rosen, Thomas Schmelter, Martin Merz, Anita Nelson
OBJECTIVE: To evaluate the efficacy and safety of a new, low-dose levonorgestrel intrauterine contraceptive system (LNG-IUS 12) for up to 5 years of use. STUDY DESIGN: In this Phase III study, 2885 nulliparous and parous women aged 18-35 years were randomized to LNG-IUS 8 or LNG-IUS 12 for 3 years. After 3 years, women using LNG-IUS 12 could continue for up to 2 additional years (5 years total). The primary outcome was occurrence of pregnancy (Pearl Index). Secondary outcomes included safety, bleeding, dysmenorrhea, discontinuations, and user satisfaction...
November 20, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
keyword
keyword
70416
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"